Cellebrite DI Ltd.
CLBT Nasdaq· Services-Prepackaged Software
Last close · Nov 9, 2026
$12.70
Key numbers, fiscal 2025
Market cap
$3.2B
P/E
41.0x
Revenue
$476M
Net income
$78.3M
Free cash flow
$160M
Operating margin
14.0%
Cellebrite DI Ltd. in 30 seconds fiscal 2025
Are sales growing?
+18.6%
Yes. Sales grew 18.6% last year.
Does it make a profit?
16.5%
Yes. It keeps 16.5% of every sale as profit.
Does profit turn into cash?
33.7%
Yes. 33.7% of sales ends up as free cash.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
41.0x
One share costs 41.0 times its yearly profit per share.
What Cellebrite DI Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 3, 2026
- Legal name
- Cellebrite DI Ltd.
- CIK
- 0001854587
Cellebrite DI Ltd. · CLBT · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $246M | $271M | $325M | $401M | $476M |
| Revenue growth | 26.3% | 9.9% | 20.1% | 23.4% | 18.6% |
| Gross margin | 82.7% | 81.3% | 83.6% | 84.4% | 84.2% |
| Operating margin | 5.6% | 0.4% | 10.2% | 14.2% | 14.0% |
| Net income | $71.4M | $121M | −$81.1M | −$283M | $78.3M |
| Net margin | 29.0% | 44.6% | −24.9% | −70.5% | 16.5% |
| Diluted EPS | $0.44 | $0.59 | −$0.43 | −$1.35 | $0.31 |
| Cash | |||||
| Cash from operations | $36.1M | $20.6M | $102M | $132M | $174M |
| Capital expenditure | $5.1M | $6.9M | $5.2M | $8.6M | $13.2M |
| Free cash flow | $30.9M | $13.7M | $96.8M | $124M | $160M |
| FCF margin | 12.6% | 5.1% | 29.8% | 30.8% | 33.7% |
| Dividends paid | $100M | $0.0M | $0.0M | — | — |
| Share buybacks | $0.0M | $0.0M | — | — | — |
| Share count change | 30.6% | 21.0% | −2.7% | 10.2% | 19.3% |
| Debt and strength | |||||
| Cash and short-term investments | $146M | $132M | $228M | $293M | $276M |
| Shareholders' equity | −$73.3M | $73.9M | $34.2M | $336M | $484M |
| Current ratio | 1.5x | 1.4x | 1.7x | 1.9x | 1.6x |
| Returns and quality | |||||
| Return on equity | — | 46,642.9% | −150.1% | −152.9% | 19.1% |
| Return on tangible equity | — | 324.5% | — | −95.6% | 27.5% |
| Piotroski F-score | 5 | 3 | 5 | 4 | 4 |
| Altman Z'' | 2.5 | 3.3 | 3.3 | 3.4 | 2.7 |
Insider trades 12 months
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$5.4M
4 insiders
Of sales under plans
2%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cellebrite DI Ltd. · CLBT · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001854587). Latest version: stoqly.net/companies/clbt. Data updated November 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.